Your browser doesn't support javascript.
loading
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma.
Rodriguez, Sara; Celay, Jon; Goicoechea, Ibai; Jimenez, Cristina; Botta, Cirino; Garcia-Barchino, Maria-José; Garces, Juan-Jose; Larrayoz, Marta; Santos, Susana; Alignani, Diego; Vilas-Zornoza, Amaia; Perez, Cristina; Garate, Sonia; Sarvide, Sarai; Lopez, Aitziber; Reinhardt, Hans-Christian; Carrasco, Yolanda R; Sanchez-Garcia, Isidro; Larrayoz, Maria-Jose; Calasanz, Maria-Jose; Panizo, Carlos; Prosper, Felipe; Lamo-Espinosa, Jose-Maria; Motta, Marina; Tucci, Alessandra; Sacco, Antonio; Gentile, Massimo; Duarte, Sara; Vitoria, Helena; Geraldes, Catarina; Paiva, Artur; Puig, Noemi; Garcia-Sanz, Ramon; Roccaro, Aldo M; Fuerte, Gema; San Miguel, Jesus F; Martinez-Climent, Jose-Angel; Paiva, Bruno.
Afiliación
  • Rodriguez S; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Celay J; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Goicoechea I; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Jimenez C; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC, Salamanca, Spain.
  • Botta C; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
  • Garcia-Barchino MJ; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Garces JJ; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Larrayoz M; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Santos S; Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.
  • Alignani D; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Vilas-Zornoza A; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Perez C; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Garate S; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Sarvide S; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Lopez A; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Reinhardt HC; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, DKTK Partner Site Essen, Center for Molecular Biotechnology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
  • Carrasco YR; Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB)-CSIC, Madrid, Spain.
  • Sanchez-Garcia I; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Larrayoz MJ; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Calasanz MJ; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Panizo C; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Prosper F; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Lamo-Espinosa JM; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Motta M; Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Tucci A; Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Sacco A; Clinical Research Development and Phase I Unit, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Gentile M; Department of Oncohematology, "Annunziata" Hospital, Cosenza, Italy.
  • Duarte S; Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.
  • Vitoria H; Hospital de S. Teotónio, Viseu, Portugal.
  • Geraldes C; Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.
  • Paiva A; Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.
  • Puig N; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC, Salamanca, Spain.
  • Garcia-Sanz R; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC, Salamanca, Spain.
  • Roccaro AM; Clinical Research Development and Phase I Unit, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Fuerte G; Mission Bio, San Francisco, CA, USA.
  • San Miguel JF; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Martinez-Climent JA; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Paiva B; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
Sci Adv ; 8(3): eabl4644, 2022 01 21.
Article en En | MEDLINE | ID: mdl-35044826
ABSTRACT
Normal cell counterparts of solid and myeloid tumors accumulate mutations years before disease onset; whether this occurs in B lymphocytes before lymphoma remains uncertain. We sequenced multiple stages of the B lineage in elderly individuals and patients with lymphoplasmacytic lymphoma, a singular disease for studying lymphomagenesis because of the high prevalence of mutated MYD88. We observed similar accumulation of random mutations in B lineages from both cohorts and unexpectedly found MYD88L265P in normal precursor and mature B lymphocytes from patients with lymphoma. We uncovered genetic and transcriptional pathways driving malignant transformation and leveraged these to model lymphoplasmacytic lymphoma in mice, based on mutated MYD88 in B cell precursors and BCL2 overexpression. Thus, MYD88L265P is a preneoplastic event, which challenges the current understanding of lymphomagenesis and may have implications for early detection of B cell lymphomas.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma de Células B / Macroglobulinemia de Waldenström / Linfoma Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Aged / Animals / Humans Idioma: En Revista: Sci Adv Año: 2022 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma de Células B / Macroglobulinemia de Waldenström / Linfoma Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Aged / Animals / Humans Idioma: En Revista: Sci Adv Año: 2022 Tipo del documento: Article País de afiliación: España